L
Lassen Therapeutics
Combining innovative science, leading technology, and unmatched know-how to create novel medicines
About Lassen Therapeutics
Lassen Therapeutics is a biotechnology company focused on developing innovative biotherapeutics to improve the lives of patients suffering from serious diseases. The company's lead program targets interleukin 11, a cytokine that plays a central role in fibrosis and the tumor microenvironment of certain cancers. By leveraging industry-leading antibody technologies, Lassen is creating a pipeline of breakthrough therapeutics aimed at addressing unmet medical needs.
Read full description
Lassen Therapeutics primarily serves patients with serious diseases, including those affected by fibrosis and cancer. The company operates in the biopharmaceutical market, which is characterized by high innovation and significant investment in research and development. Lassen's business model involves the discovery and development of novel antibody-based therapies, which are then brought to market through clinical trials and regulatory approvals.
Revenue generation for Lassen Therapeutics comes from the successful commercialization of its therapeutic products, which may include partnerships, licensing agreements, and direct sales. The company is guided by a team with a proven track record in antibody development and is driven by core values that emphasize innovation, collaboration, and patient-centricity.
At a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- San Diego, United States
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 60.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
Latest news
Press, funding announcements and product moves mentioning Lassen Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2023 | $85M | $340M | Alta Partners · Longwood Fund · BVF Partners · Frazier Healthcare Partners | ↗ |
| SERIES AOther financing | Jun 2020 | $31M | $124M | Frazier Healthcare Partners | — |
Growth signals
Latest recorded traffic for Lassen Therapeutics is 660 monthly website visits, down 15.4% over the last three months. Lassen Therapeutics's team declined 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Frazier Healthcare Partners
Alta Partners
Longwood Fund
BVF Partners
Longitude Capital
Catalio Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lassen Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lassen Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.